Amyloid β-peptide Aβ1-42 but not Aβ 1-40 attenuates synaptic AMPA receptor function

Synapse

Volumn 61, Issue 6, 2007, Pages 367-374

  Parameshwaran, Kobeeswaran ^a   Sims, Catrina ^a   Kanju, Patrick ^a   Vaithianathan, Thirumalini ^a,b   Shonesy, Brian C ^a   Dhanasekaran, Muralikrishnan ^a   Bahr, Ben A ^c   Suppiramaniam, Vishnu ^a,d  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d AUBURN UNIVERSITY   (United States)

Author keywords

AMPA receptors; Amyloid beta; Single channel; Synaptic currents

Indexed keywords

AMPA RECEPTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; LIPID BILAYER; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SENILE PLAQUE; WHOLE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; HIPPOCAMPUS; ION CHANNEL GATING; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; SYNAPSES; SYNAPTIC TRANSMISSION; SYNAPTOSOMES;

EID: 34147113790     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20386     Document Type: Article

References (44)

1. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. 2005. β-Amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20:187-198.
2. Bayer BA, Wirths O, Majtenyl K, Hartmann T, Multhaup G, Beyruther K, Czech C. 2001. Key factors in Alzheimer's Disease: β-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 11:1-11.
3. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. 2003. Amyloid β-protein (Aβ) assembly: Aβ 40 and Aβ 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100:330-335.
4. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. 1993. Intracellular accumulation of β-amyloid in cells expressing the swedish mutant amyloid precursor protein. Proc Natl Acad Sci USA 90:2092-2096.
5. Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT. 2006. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci USA 103:3410-3415.
6. Chen QS, Kagan BL, Hirakura Y, Xie CW. 2000. Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides. J Neurosci Res 60:65-72.
7. Chen YRGlabe CG. 2006. Distinct early folding and aggregation properties of Alzheimer amyloid-β peptides Aβ40 and Aβ42: Stable trimer or tetramer formation by Aβ42. J Biol Chem 281:24414-24422.
8. Clippingdale AB, Wade JD, Barrow CJ. 2001. The amyloid-β peptide and its role in Alzheimer's disease. J Peptide Sci 7:227-249.
9. Coronado R, Latorre R. 1983. Phospholipid bilayers made from monolayers on patch-clamp pipettes. Biophys J 43:231-236.
10. Cullen WK, Suh YH, Anwyl R, Rowan MJ. 1997. Block of LTP in rat hippocampus in vivo by β-amyloid precursor protein fragments. Neuroreport 8:3213-3217.
11. Freir DB, Holscher C, Herron CE. 2001. Blockade of long-term potentiation by β-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol 85:708-713.
12. Glenner GG, Wong CW. 1984. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrocascular amyloid protein. Biochem Biophys Res Commun 120:885-890.
13. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ. 1992. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Nature 359:322-325.
14. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the U.S. population: Prevalence estimates using the 2000 census. Arch Neurol 60:1119-1122.
15. Holscher C. 1998. Possible causes of Alzheimer's disease: Amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5:129-141.
16. Itoh A, Akaike T, Mokabe S, Nitta A, Iida R, Olariu A, Yamada K, Nabeshima T. 1999. Impairments of long-term potentiation in hippocampal slices of β-amyloid-infused rats. Eur J Pharmacol 382:167-175.
17. Johnson MW, Chotiner JK, Watson JB. 1997. Isolation and characterization of synaptoneurosomes from single rat hippocampal slices. J Neurosci Methods 77:151-156.
18. Kuo Y, Emmerling MR, Vigo-Pelfrey C, Kasunici TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. 1996. Water-soluble Ab (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081.
19. Laakso MP. 2002. Structural imaging in cognitive impairment and the dementias: An update. Curr Opin Neurol 15:415-421.
20. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
21. Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN. 1996. Predominant deposition of amyloid-β 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 148:1257-1266.
22. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimers disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249.
23. Muller D, Joly M, Lynch G. 1988. Contributions of quisqualate and NMDA receptors to the induction and expression of LTP. Science 242:1694-1697.
24. Nichols MR, Moss MA, Reed DK, Cratic-McDaniel S, Hoh JH, Rosenberry TL. 2005. Amyloid-β protofibrils differ from amyloid-β aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J Biol Chem 280:2471-2480.
25. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Ap and synaptic dysfunction. Neuron 39:409-421.
26. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DM, Neary D, Snowden JS, Bowen DM. 1987. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 48:8-15.
27. Raymond CR, Ireland DR, Abraham WC. 2003. NMDA receptor regulation by amyloid-β does not account for its inhibition of LTP in rat hippocampus. Brain Res 968:263-272.
28. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ. 1993. B-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 90:10836-10840.
29. Rowan MJ, Klyubin I, Wang QAnwyl R. 2004. Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity. Exp Gerontol 39:1661-1667.
30. Satoh Y, Hirakura Y, Shibayama S, Hirashima N, Suzuki T, Kirino Y. 2001. β-Amyloid peptides inhibit acetylcholine release from cholinergic presynaptic nerve endings isolated from an electric ray. Neurosci Lett 302:97-100.
31. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298:789-791.
32. Shemer I, Holmgren C, Min R, Fulop L, Zilberter M, Sousa KM, Farkas T, Hartig W, Penke B, Burnashev N, Tanila H, Zilberter Y, Harkany T. 2006. Non-fibrillar β-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci 23:2035-2047.
33. Stoppini L, Buchs PA, Muller D. 1991. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37:173-182.
34. Szegedi V, Juhász G, Budai D, Penke B. 2005. Divergent effects of Aβ1-42 on ionotropic glutamate receptor-mediated responses in CA1 neurons in vivo. Brain Res 1062:120-126.
35. Vaithianathan T, Manivannan K, Kleene R, Bahr BA, Dey MP, Dityatev A, Suppiramaniam V. 2005. Single channel recordings from synaptosomal AMPA receptors. Cell Biochem Biophys 42:75-85.
36. Verdier Y, Penke B. 2004. Binding sites of amyloid β-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr Protein Pept Sci 5:19-31.
37. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
38. Wang Q, Rowan MJ, Anwyl R. 2004. β-Amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24:6049-6056.
39. Wang HY, Lee DHS, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. 2000. β-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626-5632.
40. Watt AJ, Sjostrom PJ, Hausser M, Nelson SB Turrigiano GG. 2004. A proportional but slower NMDA potentiation follows AMPA potentiation in LTP. Nat Neurosci 7:518-524.
41. Wu J, Anwyl R, Bowan MJ. 1995. β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 6:2409-2413.
42. Ye L, Qiao JT. 1999. Suppressive action produced by β-amyloid peptide fragment 31-35 on long-term potentiation in rat hippocampus is N-methyl-D-aspartate receptor-independent: It's offset by (-)huperzine A. Neurosci Lett 275:187-190.
43. Zhao D, Watson JB, Xie CW. 2004. Amyloid β prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol 92:2853-2858.
44. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M. 2003. Amyloid β-protein (Aβ)1-40 protects neurons from damage induced by Aβ1-42 in culture and in rat brain. J Neurochem 87:609-619.